跳到主要內容區塊
考生 在校生 教職員 校友 訪客
單位自訂圖片
返回
文字大小: 小 中 大
:::
:::

黃旭山 教授

🎓 JOINT APPOINTMENT PROFESSOR
Prof. Dr. Hsu-Shan Huang
Prof. Dr. Hsu-Shan Huang
黃 旭 山
📞 Office & Contact
Taipei Medical University, Shungho Campus 11F, Teaching Building,
No. 301, Yuantong Rd., Zhonghe Dist., New Taipei City 235, Taiwan
Telephone: 02-6620-2589  ext. 11103
Cellphone: 0938-396-023
E-mail: huanghs99@tmu.edu.tw / huanghs99@gmail.com
💼 Current Appointments
  • Professor, Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taiwan
  • Professor, Ph.D. Program in Biotechnology Research and Development, College of Pharmacy, Taipei Medical University
  • Adjunct Professor, School of Pharmacy, National Defense Medical Center (NDMC), Taipei, Taiwan
🎓 Education
1992/03–1996/06 Dr. rer. nat., Institute of Pharmacy, University of Regensburg, Germany
1985/07–1987/06 M.S., Graduate Institute of Pharmacy, National Defense Medical Center, Taipei, Taiwan
1981/07–1985/06 B.S., School of Pharmacy, National Defense Medical Center, Taipei, Taiwan
🏛 Professional Experiences
2014–Present Professor, Taipei Medical University, Taipei, Taiwan
2014–2017 Secretary General, Consortium for Globalization of Chinese Medicine (CGCM), Taiwan Region, TMU
2012–2013 Director (Chief Pharmacist), Department of Pharmacy Practice, Tri-Service General Hospital (TSGH), NDMC
2008–2012 Dean / Professor, School of Pharmacy, NDMC
2010–2012 Director, Department of Research and Development, NDMC
2006–2014 Adjunct Professor, TIGP Program, Academia Sinica, Taipei, Taiwan
2006–2007 Visiting Scientist, The Scripps Research Institute, USA
2005–2014 Professor, School of Pharmacy, NDMC, Taipei, Taiwan
1996–2005 Associate Professor, School of Pharmacy, NDMC, Taipei, Taiwan
1997–1998 Visiting Professor, University of Pavia, Italy
2000–2001 Visiting Scientist, Institute of Pharmacy, University of Münster, Germany
1987–1992 Lecturer, School of Pharmacy, NDMC, Taipei, Taiwan
🔗 Research Profiles
Publications (TMU Hub): https://hub.tmu.edu.tw/zh/persons/hsu-shan-huang/publications/
Scopus ID: 7405610149 ; 0000-0001-8162-5608
ORCID: https://orcid.org/0000-0001-8162-5608
📚 Bibliography (Selected Publications)
※ Showing items 1–68 (Scroll down to view more)
  1. Kuo, Y.C.; Ajibolac, M.I.; Lukmand, H.Y.; Lawal, B.; Lung-Ching Chenf,g; Sheng-Liang Huangh; Olawale David Ajayii; Sunday Amos Onikannij,k,l; Saheed Sabiud; Leandro Miranda-Alvesj,k*; Huang, H.S.*, Investigating the Antidiabetic Effects of Calotropis procera: Preclinical Assessment, Food Science & Nutrition (Food Sci. Nutr.), 2026, accepted. (IF: 3.8; Ranking: 59/181=32.6%, FOOD SCIENCE & TECHNOLOGY, 2024)
  2. Ho, H.H.; Wang, S.C.; Huang, H.S.;* Yang, P.M.*, 2026, Jan, NSC777201 exhibits anticancer activity against colorectal cancer cells by inducing multiple types of cell death, Cancer Cell Int., 2026, 26:41. Link
  3. Agwupuye, E.I.¶; Agboola, A.R.¶; Kuo, Y.C.¶; Itam, A.H.; Ezeayinka, L.U.; Atangwho, I.J.; Ayeyemi, B.M.; Edema, A.A.; Lawal, B.; Alotaibi, M.O.; Almohmadi, N.H.; Batiha, G.E.S.; El-Sabbagh, N.M.; Huang, H.S.*, 2025, Oct, Theobroma cacao seed extracts attenuate dyslipidemia and oxidative stress in L-NAME induced hypertension in Wistar rats, Int. J. Med. Sci., 2025, 22(16), 4509-4522. Link
  4. Tang, S.L.; Rachmawati Sumitra, M.; Chen, L.C.; Liu, F.C.; Hsu, H.L.; Kuo, Y.C.; Ansar, M.; Huang, S.L.; Lee, S.Y.; Wang, H.J.; Lawal, B.; Wu, A.T.H.; Wen, Y.T.; Huang, H.S.*, 2025 Oct, Machine learning-driven discovery of NSC828779 as a multi-mechanistic NLRP3 inflammasome inhibitor for inflammatory diseases, Comput. Biol. Med., 2025, 197, 111110.
  5. Tang, S.L.; Rachmawati Sumitra, M.; Kuo, Y.C.; Hsu, H.L.; Ansar, M.; Huang, S.L.; Lee, S.Y.; Wang, H.J.; Lawal, B.; Wu, A.T.H.; Chen, L.C.; Huang, H.S.*, 2025 Jul, Computer-aided drug discovery of a dual-target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI-60, Comput. Biol. Med., 2025, 193, 110445.
  6. Kuo, Y.C.; Lawal, B.; Lukman, H.Y.; Chen, L.C.; Huang, S.L.; Chen, Y.F.; Fadaka, A.O.; Olawale, F.; Olasupo, A.; Ajenifujah, O.T.; Fouad, D.; Papadakis, M.; Batiha, G.E.S.; Sabiu, S.; Wu, A.T.H*; Huang, H.S.* 2025 March, Bioprospection of Hura crepitans metabolites against oxidative stress and inflammation: An in vitro and in silico exploration, Int. J. Med. Sci., 2025, 22(8):1837-1851.
  7. Lukman, H.Y.; Kuo, Y.C.; Owolabi, M.S.; Lawal, B.; Chen, L.C.; Ajenifujah, O.T.; Fadaka, A.O.; Olawale, F.; Onikanni, A.S.; Saidu, S.; Mahmoud, M.H.; Batiha, G.E.; Wu, T.H.A.*; Huang, H.S.* 2024 Oct, Evaluation of terpenes rich Hura crepitans Extract on Glucose Regulation and Diabetic Complications in STZ-induced Diabetic Rats, Biomed. Pharmacother., 2024, 179, 117308.
  8. Srivastavaa, P.; Yadav, V.K.; Chang, T.H.; Su, E.C.Y.; Lawal, B.; Wu, T.H.A.*; Huang, H.S.* 2024 June, In-silico analysis of TMEM2 as a pancreatic adenocarcinoma and cancer-associated fibroblast biomarker, and functional characterization of NSC777201, for targeted drug development, Am. J. Cancer Res., 2024, 14(6), 3010-3035.
  9. Rachmawati Sumitra, M.; Chen, L.C.; Tsai, W.C.; Ansarf, M.; Lawal, B.; Mokgautsi, N.; Guh, J.H.; Wu, T.H.A.*; Huang, H.S.* 2024 Jan, Structure-based design, synthesis and biological evaluation of N-substituted 6H-thiochromeno[2,3-c]quinolin-12(12H)-ones as potential breast cancer drugs, Arab. J. Chem., 2024, 17, 105423.
  10. Chinyama, H.A.; Wei, L.; Mokgautsi, N.; Lawal, B.; Wu, T.H.A.*; Huang, H.S.* 2023 Nov, Identification of CDK1, PBK, and CHEK1 as an oncogenic signature in glioblastoma: A bioinformatics approach to repurpose dapagliflozin as a therapeutic agent. Int. J. Mol. Sci., 2023, 24, 16396.
  11. Kuo, Y.C.; Cheng, C.Y.; Chen, L.C.; Lawal, B.; Shih, P.J.*; Huang, H.S.* 2023 Oct, Diagnosis of kidney insufficiency by using the pressure waveforms of wrist-type sphygmomanometers: Toward a convenient point-of-care device, Am. J. Transl. Res., 2023;15(10):6015-6025.
  12. Chiang, Y.C.; Leu, W.J.; Chen, Y.C.; Ye, P.C.; Hsiao, Y.C.; Hsu, J.L.; Hsu, L.C.; Huang, H.S.*; Guh, J.H.* 2023 Aug, Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer, Prostate, 2023, 1-15.
  13. Lawal, B.; Kuo, Y.C.; Onikanni, A.S.; Chen, Y.F.; Abdulrasheed-Adeleke, T.; Fadaka, A.O.; Olugbodi, J.O.; Lukman, H.Y.; Olawale, F.; Mahmoud, M.H.; El-Saber Batiha, G.; Wu, T.H.A.*; Huang, H.S.* 2023 Jul, Computational identification of novel signature of T2DM-induced nephropathy and therapeutic potential of bioactive compounds from Azanza garckeana, Am. J. Transl. Res., 2023, 15(7), 4504-4520.
  14. Huang, H.S.; Chiang, I.T.; Lawal, B.; Weng, Y.S.; Jeng, L.B.; Kuo, Y.C.; Liu, Y.C.; Hsu, F.T.* 2023 Jul, A novel isotope-labeled small molecule probe CC12 for anti-glioma via suppressing LYN-mediated progression and activating apoptosis pathways, Int. J. Biol. Sci., 2023, 19(10), 3209-3225.
  15. Chen, L.C.; Mokgautsi, N.; Kuo, Y.C.; Wu, T.H.A.*; Huang, H.S.* 2023 Jul, In Silico Evaluation of HN-N07 small molecule as an inhibitor of angiogenesis and lymphangiogenesis oncogenic signatures in non-small cell lung cancer, Biomedicine, 2023, 11(7), 2011.
  16. Lawal, B.; Kuo, Y.C.; Wu, T.H.A.*; Huang, H.S.* 2023 June, Therapeutic potential of EGFR/mTOR/Nf-kb targeting small molecule for the treatment of non-small cell lung Cancer, Am. J. Cancer Res., 2023, 13(6), 2598-2616.
  17. Nivrutti Khedkar, H.; Chen, L.C.; Kuo, Y.C.; Wu, T.H.A.*; Huang, H.S.* 2023 June, Multi-omics identification of genetic alterations in head and neck squamous cell carcinoma and therapeutic efficacy of HNC018 as a novel multi-target agent for c-MET/STAT3/AKT signaling axis, Int. J. Mol. Sci., 2023, 24(12), 10247.
  18. Abdulrasheed-Adeleke, T.; Lawal, B.; Agwupuye, E.I.; Kuo, Y.C.; Ene, A.M.; Ekoh, O.F.; Lukman, H.Y.; Onikanni, A.S.; Olawale, F.; Saidu, S.; Ibrahim, Y.O.; Al Ghamdi, M.A.S.; Aggad, S.S.; Alsayegh, A.A.; Aljarba, N.H.; El-Saber Batiha, G.; Wu, T.H.A.*; Huang, H.S.* 2023 June, Apigetrin-enriched pulmeria alba methanolic extract prevents assault of STZ on pancreatic β-cells and neuronal oxidative stress..., Biomed Pharmacother, 2023, 162, 114582.
  19. Lawal, B.; Tsai, S.K.; Wu, T.HA.*; Huang, H.S.* 2023 Feb, In silico study of novel niclosamide derivatives, SARS-CoV-2 nonstructural proteins catalytic residue-targeting small molecules drug candidates, Arab. J. Chem., 2023, 16, 104654.
  20. Mokgautsi, N.; Kuo, Y.C.; Chen, C.H.; Huang, Y.J.; Wu, T.H.A.*; Huang, H.S.* 2023 Jan, Multi-omics study of a novel naturally derived small molecule, NSC772864, as a potential inhibitor of proto-oncogenes regulating cell cycle progression in colorectal cancer, Cells, 2023, 12(2), 340.
  21. Mokgautsi, N.; Kuo, Y.C.; Huang, Y.J.; Chen, C.H.; Mukhopadhyay, D.; Wu, T.H.A.*; Huang, H.S.* 2023 Jan, Preclinical evaluation of a novel small molecule LCC-21 to suppress colorectal cancer malignancy by inhibiting angiogenic and metastatic oncogenic signatures, Cells, 2023, 12(2), 266.
  22. Chen, Y.F.; Lawal, B.; Huang, L.J.; Kuo, S.C.; Rachmawati Sumitra, M.; Mokgautsi, N.; Lin, H.Y.;* Huang, H.S.*, 2023 Jan, In vitro and in silico biological studies of 4-phenyl-2-quinolone (4-PQ) derivatives as anticancer agents, Molecules, 2023, 28(2), 555.
  23. Hogan, I.A.; Kuo, Y.C.; Abubakar, A.N.; Lawal, B.; Agboola, A.R.; Lukman, H.Y.; Onikanni, A.S.; Olawale, F.; Fadaka, A.O.; Ibrahim, Y.O.; Babalola, S.B.; El-Saber Batiha, G.; Albogami, S.M.; Alorabi, M.; Waard, M.D.; Huang, H.S.* 2023 Feb, Attenuation of hyperglycemia-associated dyslipidemic, oxidative, cognitive, and inflammatory crises via modulation of neuronal ChEs/NF-κB/COX-2/NOx, and hepatorenal functional deficits by the Tridax procumbens methanol extract, Biomed. Pharmacother., 2023, 158, 114114.
  24. Lawal, B.; Kuo, Y.C.; Khedkar, H.; Mokgautsi, N.; Rachmawati Sumitra, M.; Wu, T.H.A.*; Huang, H.S.* 2022 Nov, Deciphering the immuno-pathogenic role of FLT, and evaluation of a novel dual inhibitor of topoisomerases and mutant-FLT3 for treating leukemia, Am. J. Cancer Res., 2022, 12(11), 5140-5159.
  25. Alozieuwa, U.B.; Lawal, B.; Sani, S.; Onikanni, A.S.; Osuji, O.; Ibrahim, Y.O.; Babalola, S.B.; Mostafa-Hedeab, G.; Alsayegh, A.A.; Albogami, S.; Batiha, G.E.S.; Wu, T.H.A.*; Huang, H.S.*; Conte-Junior, C.A. 2022 Jul, Luteolin-rich extract of thespesia garckeana F. hoffm. (Snot Apple) contains potential drug-like candidates and modulates glycemic and oxidoinflammatory aberrations in experimental animals, Oxid. Med. Cell Longev., 2022, 1215097.
  26. Lawal, B.; Kuo, Y.C.; Rachmawati Sumitra, M.; Wu, T.H.A.*; Huang, H.S.* 2022 Sep, Identification of novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small molecule derivative of quinolone, Comput. Biol. Med., 2022, 148, 105814.
  27. Lawal, B.; Sani, S.; Onikanni, A.S.; Ibrahim, Y.O.; Agboola, A.R.; Jigam, A.A.; Lukman, Ha.Y.; Olawale, F.; Jigam, A.A.; Batiha, G.E.S.; Babalola, S.B.; Mostafa-Hedeab, G.; Lima, C.M.G.; Wu, T.H.A.*; Huang, H.S.*; Conte-Junior, C.A., 2022 June, Preclinical anti-inflammatory and antioxidant effects of azanza garckeana in STZ-induced glycemic-impaired rats, and pharmacoinformatics of it major phytoconstituents, Biomed. Pharmacother., 2022, 152, 113196.
  28. Lawal, B.; Wu, T.H.A.*; Huang, H.S.* 2022 May, Leveraging bulk and single-cell RNA sequencing data of NSCLC tumor microenvironment and therapeutic potential of NLOC-15A, a novel multitarget small molecule, Front. Immunol., 2022, 13:872470.
  29. Mokgautsi, N.; Kuo, Y.C.; Tang, S.L.; Liu, F.C.; Chen, S.J.; Wu, T.H.A.*; Huang, H.S.* 2022 Jan, Anticancer activities of 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c] quinolin-11-one (SJ10) in glioblastoma multiforme (GBM) chemoradiore-sistant cell cycle-related oncogenic signatures, Cancers, 2022, 14(1), 262.
  30. Thomashire A.G.; Chen, M.M.; Czosseck, A.; Chen, H.P.; Huang, H.S.*; Lundy, D.J.*, 2022 Jan, Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer, J. Control Release, 2022, 342, 31-43.
  31. Yang, S.R.; Hung, S.C.; Chu, L.C.J.; Hua, K.F.; Wei, C.W.; Tsai, I.L.; Kao, C.C.; Sung, C.C.; Wu, C.Y.; Chen, A.; Wu, T.H.A.; Liu, F.C.; Huang, H.S.*; Ka, S.M.*, 2021 Nov, NSC828779 alleviates renal tubulointerstitial lesions involving interleukin-36 signaling in mice, Cells, 2021, 10(11), 3060-3078.
  32. Lawal, B.; Kuo, Y.C.; Tang, S.L.; Liu, F.C.; Wu, T.H.A.*; Lin, H.Y.*; Huang, H.S.* 2021 Oct, Transcriptomic-based identification of the immuno-oncogenic signature of cholangiocarcinoma for HLC-018 multi-target therapy exploration, Cells, 2021, 10(11), 2873-2896.
  33. Lawal, B.; Kuo, Y.C.; Wu, T.H.A.*; Huang, H.S.* 2021 Sep, In vivo pharmacokinetic and anticancer studies of HH-N25, a selective inhibitor of topoisomerase I, and hormonal signaling for treating breast cancer, J. Inflamm. Res., 2021, 14, 4901-4913.
  34. Wu, T.H.A.*; Huang, H.S.*; Wen, Y.T.; Lawal, B.; Mokgautsi, N.; Huynh, T.T.; Hsiao, M.; Li, W.* 2021 Sep, A preclinical investigation of GBM-N019 as a potential inhibitor of glioblastoma multiform via exosoamal mTOR/CDK6/STAT3 signaling, Cells, 2021, 10(9), 2391-2411.
  35. Angom, R.S.; Zhu, J.; Wu, T.H.A.; Rachmawati-Sumitra, M.; Pham, V.; Dutta, S.; Wang, E.; Madamsetty, V.; Perez Cordero, G.D.; Huang, H.S.; Mukhopadhyay, D.; Wang, Y.* 2021 Sep, LCC-09, a novel salicylanilide derivative, exerts anti-inflammatory effect in vascular endothelial cells, J. Inflamm. Res., 2021, 14, 4551-4565.
  36. Lawal, B.; Wang, Y.C.; Wu, T.H.A.*; Huang, H.S.*, 2021 Aug, Pro-oncogenic c-Met/EGFR, biomarker signatures of the tumor microenvironment are clinical and therapy response prognosticators in colorectal cancer, and therapeutic targets of 3-phenyl-2H-benzo[e][1,3]-oxazine-2,4(3H)-dione derivatives, Front. Pharmacol., 2021, 12:691234.
  37. Huang, T.H.; Mokgautsi, N.; Huang, Y.J.; Wu, T.H.A.*; Huang, H.S.*, 2021 Aug, Comprehensive omics analysis of a novel small-molecule inhibitor of chemoresistant oncogenic signatures in colorectal cancer cell with antitumor effects, Cells, 2021, 10(8), 1970-1991.
  38. Yang, S.R.; Hua, K.F.; Wu, C.Y.; Chen, A.; Weng, J.C.; Tsai, Y.L.; Wan, C.J.; Lee, C.C.; Chan, J.F.; Hsieh, C.Y.; Hsu, Y.J.; Wu, C.C.; Mukhopadhyay, D.; Huang, H.S.*; Liu, F.C.*; Ka, S.M.*, 2021 July, Cf-02, a novel benzamide-linked small molecule, blunts NF-κB activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice, FASEB J., 2021, 35(8), e21785.
  39. Lawal, B.; Kuo, Y.C.; Wu, T.H.A.*; Huang, H.S.*, 2021 July, BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase, Int. J. Biol. Sci., 2021, 17(12), 3224-3238.
  40. Lawal, B.; Lo, W.C.; Mokgautsi, N.; Rachmawati Sumitra, M.; Khedkar, H.; Wu, T.H.A.*; Huang, H.S.*, 2021 Jun, A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K/AKT/mTOR/MEK in multiple cancers, Am. J. Cancer Res., 2021, 11(6):2590-2617.
  41. Khedkar Nivrutti H.; Wang, Y.C.; Yadav, V.K.; Srivastava, P.; Lawal, B.; Mokgautsi, N.; Rachmawati Sumitra, M.; Wu, T.H.A.*; Huang, H.S.*, 2021 May, In-silico evaluation of genetic alterations in ovarian carcinoma and therapeutic efficacy of NSC777201, as a novel multi-target agent for TTK, NEK2, and CDK1, Int. J. Mol. Sci., 2021, 22(11):5895.
  42. Mokgautsi, N.; Wang, Y.C.; Lawal, B.; Khedkar, H.; Rachmawati Sumitra, M.; Wu, T.H.A.*; Huang, H.S.*, 2021 May, Network pharmacological analysis through a bioinformatics approach of novel NSC765600 and NSC765691 compounds as potential inhibitors of CCND1/CDK4/PLK1/CD44 in multiple cancer types, Cancers, 2021, 13(11), 2523.
  43. Lawal, B.; Lee, C.Y.; Mokgautsi, N.; Rachmawati Sumitra, M.; Khedkar, H.; Wu, T.H.A.*; Huang, H.S.*, 2021 March, mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 are druggable candidates for N-(2,4-difluorophenyl)-2',4'-difluoro-4-hydroxybiphenyl-3-carboxamide (NSC765598), with consequent anticancer implications, Front. Oncol., 2021, 11:656738.
  44. Mokgautsi, N.; Wen, Y.T.; Lawal, B.; Khedkar, H.; Rachmawati Sumitra, M.; Wu, T.H.A.*; Huang, H.S.*, 2021 Feb, An integrated bioinformatics study of a novel niclosamide derivative, NSC765689, a potential GSK3β/β-Catenin/STAT3/CD44 suppressor with anti-glioblastoma properties, Int. J. Mol. Sci., 2021, 22(5), 2464.
  45. Lawal, B.; Lu, Y.L.; Mokgautsi, N.; Khedkar, H.; Rachmawati Sumitra, M.; Wu, T.H.A.*; Huang, H.S.* 2021 Jan, Pharmacoinformatics and preclinical studies of NSC765690 and NSC765599, potential STAT3/CDK2/4/6 inhibitors with antitumor activities against NCI60 human tumor cell lines, Biomedicines, 2021, 9(1):92.
  46. Yang, S.R.; Hua, K.F.; Takahata, A.; Wu, C.Y.; Hsieh, C.Y.; Chiu, H.W.; Chen, C.H.; Mukhopadhyay, D.; Suzuki, Y.; Ka, S.M.*; Huang, H.S.*; Chen, A.* 2021 Apr, CC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice, J. Pathol., 2021, 253(4), 427-441.
  47. Ahmed, A.A.A.; Lee, Y.R.; Wu, T.H.A.; Yadav, V.K.; Yu, D.S.; Huang, H.S.* 2021 Feb, Structure-based strategies for synthesis and lead optimization of N-substituted anthra[1,2-c][1,2,5] thiadiazole-6,11-dione derivatives as potential multi-target anticancer agents, Arab. J. Chem., 2021, 14(2), 102884-102907.
  48. Lee, J.C.; Wu, T.H.A.; Chen, J.H.; Huang, W.Y.; Lawal, B.; Mokgautsi, N.; Huang, H.S.*; Ho, C.L.*, 2020 Dec, HNC0014, a multi-targeted small-molecule, inhibits head and neck squamous cell carcinoma by suppressing c-Met/STAT3/CD44/PD-L1 onocoimmune signature and eliciting antitumor immune responses, Cancers, 2020, 12(12), E3759.
  49. Yadav, V.K.; Huang, Y.J.; George, T.A.; Wei, P.L.; Sumitra-Rachmawati, M.; Ho, C.L.; Chang, T.H.; Wu, T.H.A.*; Huang, H.S.* 2020 Jun, Preclinical evaluation of the novel small-molecule MSI-N1014 for treating drug-resistant colon cancer via the LGR5/β-catenin/miR-142-3p network and reducing cancer-associated fibroblast transformation, Cancers, 2020, 12(6), 1590.
  50. Su, Y.S.; Chen, H.; Hsieh, W.S.; Chen, C.H.; Jiang, H.; Huang, H.S.; Chang, D.M.; Huang, S.L.; Sun, W.H.* 2020 May, TDAG8 deficiency reduces satellite glial number and proinflammatory macrophage number to relieve rheumatoid arthritis disease severity and chronic pain, J. Neuroinflamm., 2020, 17(1), 170-186.
  51. Kung, C.C.; Dai, S.P.; Chiang, H.; Huang, H.S.; Sun, W.H.* 2020 May, Temporal expression patterns of distinct cytokines and M1/M2 macrophage polarization regulate rheumatoid arthritis progression, Mol. Biol. Rep., 2020, 47:3423-3437.
  52. Fann, L.Y.; Shih, J.H.; Tseng, J.H.; Huang, H.S.*; Hsiao, S.H.*, 2020 Apr, CC12 induces apoptotic cell death and cell cycle arrest in human glioblastoma cell line and mouse xenograft model, Molecules, 2020, 25(8), E1793.
  53. Chiu, Y.S.; Wu, J.L.; Yeh, C.T.; Yadav, V.K.; Huang, H.S.*; Wang, L.S.*, 2020 Apr, γ-Mangostin isolated from Garcinia mangostana L. suppresses inflammation and alleviates symptoms of osteoarthritis via modulating miR-124-3p/IL-6/NF-κB signaling, Aging (Aging-US), 2020, 12(8):6630-6643.
  54. Hsieh, C.L.; Huang, H.S.; Chen, K.C.; Saka, T.; Chiang, C.Y.; Chung, L.W.K.; Sung, S.Y.*, 2020 Jan, A novel salicylanilide derivative induces autophagy cell death in castration-resistant prostate cancer via ER stress-activated PERK signaling pathway, Mol. Cancer Ther., 2020, 19, 101-111.
  55. Shen, C.J.; Lin, P.L.; Lin, H.C.; Cheng, Y.W.; Huang, H.S.*; Lee, H.* 2019 Dec, RV-59 suppresses cytoplasmic Nrf2-mediated 5-fluorouracil resistance and tumor growth in colorectal cancer, Am. J. Cancer Res., 2019, 9(12), 2789-2796.
  56. Chen, C.L.; Chen, T.C.; Lee, C.C.; Shih, L.C.; Lin, C.Y.; Hsieh, Y.Y.; Ahmed, A.A.A.; Huang, H.S.* 2019 Dec, Synthesis and evaluation of new 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer agents, Arab. J. Chem., 2019, 12, 3503-3516.
  57. Chen, T.C.; Guh, J.H.; Hsu, H.W.; Chen, C.L.; Lee, C.C.; Wu, C.L.; Lee, Y.R.; Lin, J.J.; Yu, D.S.*; Huang, H.S.* 2019 Dec, Synthesis and biological evaluation of anthra[1,9-cd]pyrazol-6(2H)-one scaffold derivatives as potential anticancer agents, Arab. J. Chem., 2019, 12, 2864-2881.
  58. Chen, T.C.; Yu, D.S.; Chen, S.J.; Chen, C.L.; Lee, C.C.; Hsieh, Y.Y.; Chang, L.C.; Guh, J.H.; Lin, J.J.*; Huang, H.S.* 2019 Dec, Design, synthesis and biological evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhibitory properties as potential anticancer agents, Arab. J. Chem., 2019, 12, 4348-4364.
  59. Madamsetty, V.S.; Pal, K.; Dutta, S.K.; Wang, E.; Thompson, J.R.; Banerjee, R.K.; Caulfield, T.R.; Mody, K.; Yen, Y.; Mukhopadhyay, D.; Huang, H.S.* 2019 Oct, Design and evaluation of PEGylated liposomal formulation of a novel multikinase inhibitor for enhanced chemosensitivity and inhibition of metastatic pancreatic ductal adenocarcinoma, Bioconjugate Chem., 2019, 30(10), 2703-2713.
  60. Wen, Y.T.; Wu, T.H.A.; Bamodu, O.A.; Wei, L.; Lin, C.M.; Yen, Y.; Chao, T.Y.; Mukhopadhyay, D.; Hsiao, M.; Huang, H.S.* 2019 Sep, A novel multi-target small molecule, LCC-09 inhibits stemness and therapy-resistant phenotypes of Glioblastoma cells by increasing miR-34a and deregulating the DRD4/Akt/mTOR signaling axis, Cancers, 2019, 11(10).
  61. Lu, J.W.; Ho, L.J.; Lai, J.H.; Huang, H.S.; Lee, C.C.; Lin, T.Y.; Lien, S.B.; Lin, L.C.; Chen, L.W.; Gong, Z.; Shen, M.C.; Liu, F.C., 2019 Sep, Anti-inflammatory and anti-osteoarthritis effects of Cm-02 and Ck-02, Biochem. Bioph. Res. Co., 2019, 517, 155-163.
  62. Wu, C.L.; Chen, C.L.; Huang, H.S.; Yu, D.S. 2018 Aug, A new niclosamide derivatives-B17 can inhibit urological cancers growth through apoptosis related pathway, Cancer Med-US, 2018, 7, 3945-3954.
  63. Liu, F.C.; Lu, J.W.; Chien, C.Y.; Huang, H.S.; Lee, C.C.; Lien, S.B.; Lin, L.C.; Chen, W.C.; Ho, Y.J.; Shen, M.C.; Ho, L.J.; Lai, J.H.* 2018 May, Arthroprotective effects of Cf-02 sharing structural similarity with quercetin, Int. J. Mol. Sci., 2018, 19, 1453-1466.
  64. Hsu, F.T.; Liu, H.S.; Ahmed A.A.A.; Tsai, P.H.; Kao, Y.C.; Lu, C.F.; Huang, H.S.; Chen, C.Y.* 2018 Apr, Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system, Nanomed.: Nanotechnol. Biol. Med., 2018, 14, 1019–1031.
  65. Wu, J.L.; Lee, C.H.; Yang, C.T.; Chang, C.M.; Li, G.; Cheng, C.K.; Chen, C.H.; Huang, H.S.*; Lai, Y.S.* 2018 Feb, Novel technique for repairing posterior medial meniscus root tears using porcine knees and biomechanical study, PLoS One, 2018, 13(2): e0192027.
  66. Fann, L.Y.; Chen, Y.; Chu, D.C.; Weng, S.J.; Chu, H.C.; Wu, T.H.A.; Lee, J.; Ali, A.A.A.; Chen, T.C.; Huang, H.S.*; Ma, K.H.* Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways, Oncotarget, 2018, 9(15), 11922-11937.
  67. Liu, F.L.; Chen, C.L.; Lee, C.C.; Wu, C.C.; Hsu, T.H; Tsai, C.Y.; Huang, H.S.; Chang, D.M.*; The simultaneous inhibitory effect of niclosamide on RANKL-induced osteoclast formation and osteoblast differentiation, Int. J. Med. Sci. 2017, 14(9), 840-852.
  68. Ahmed A.A.A.; Hsu, F.T.; Hsieh, C.L.; Shiau, C.Y.; Chiang, C.H.; Wei, Z.H.; Chen, C.Y.*; Huang, H.S.* Erlotinib-conjugated iron oxide nanoparticles as a smart targeted theranostic probe for MRI, Sci. Rep., 2016, 6:36650.
  69. Lin, Y.H.; Chuang, S.M.; Chen, C.L.; Jeyachandran, S.; Lo, S.C.; Wu, P.C.; Huang, H.S.*; Hou, M.H.* Selective recognition and stabilization of new ligands targeting the potassium form of the human telomeric G-quadruplex DNA, Sci. Rep., 2016, 6, 31019-31028.
  70. Wu, D.W.; Chen, T.C.; Huang, H.S.*; Lee, H.* TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small cell lung cancer cells, Cell Death Dis., 2016, 7, e2290.
  71. Lee, C.C.; Chen, C.L.; Liu, F.L., Chiou, C.Y.; Chen, T.C.; Wu, C.C.; Sun, W.H.; Chang, D.M.*; Huang, H.S.* Development of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium derivatives as a new class of RANKL-induced osteoclastogenesis inhibitors, Arch. Pharm., 2016, 349, 342-355.
  72. Chen, C.L.; Lee, C.C.; Liu, F.L.; Chen, T.C.; Ahmed A.A.A.; Chang, D.M.*; Huang, H.S.* Design, synthesis and SARs of novel salicylanilides as potent inhibitors of the RANKL-induced osteoclastogenesis and bone resorption, Eur. J. Med. Chem., 2016, 117, 70-84.
  73. Ahmed A.A.A.; Lee, Y.R.; Chen, T.C.; Chen, C.L.; Lee, C.C.; Shiau, C.Y.; Chiang, C.H.; Huang, H.S.* Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds: biological evaluation, characterization & molecular targets determination, PLoS One, 2016, 11(4), e0154278.
  74. Lee, C.C.; Lo, Y.; Ho, L.J.; Lai, J.H.; Lien, S.B.; Lin, L.C.; Chen, C.L.; Chen, T.C.; Liu, F.C.*; Huang, H.S.* A new application of parallel synthesis strategy for discovery of amide-linked small molecules as potent chondroprotective agents in TNF-α-stimulated chondrocytes, PLoS One, 2016, 11(3), e0149317.
  75. Chang, L.C.; Chen, T.C.; Chen, S.J.; Chen, C.L.; Lee, C.C.; Wu, S.H.; Yen, Y.; Huang, H.S.*; Lin, J.J.* Identification of a new class of WNT1 inhibitor: cancer cells migration, G-quadruplex stabilization and target validation, Oncotarget, 2016, 7(42), 67986-68001.
  76. Chen, T.C.; Wu, C.L.; Lee, C.C.; Chen, C.L.; Yu, D.S.*; Huang, H.S.* Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents, Eur. J. Med. Chem., 2015, 103, 615-627.
  77. Lee, Y.R.; Chen, T.C.; Lee, C.C.; Chen, C.L.; Ahmed A.A.A.; Tikhomirov, A.; Guh, J.H.; Yu, D.S.*; Huang, H.S.* Ring fusion strategy for synthesis and lead optimization of sulfur-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivatives as promising scaffold of antitumor agents, Eur. J. Med. Chem., 2015, 102, 661-676.
  78. Lee, C.C.; Liu, F.L.; Chen, C.L.; Chen, T.C.; Chang, D.M.*; Huang, H.S.* Novel inhibitors of RANKL-induced osteoclastogenesis: Deign, synthesis, and biological evaluation of 6-(2,4-difluorophenyl)-3-phenyl-2H-benzo [e][1,3]oxazine-2,4(3H)-diones, Bioorg. Med. Chem., 2015, 23, 4522-4532.
  79. Lee, C.C.; Liu, F.L.; Chen, C.L.; Chen, T.C.; Chang, D.M.*; Huang, H.S.* Discovery of 5-(2',4'-difluorophenyl)-salicylanilides as new inhibitors of receptor activator of NF-B ligand (RANKL)-induced osteoclastogenesis, Eur. J. Med. Chem., 2015, 98, 115-126.
  80. Chen, C.L.; Liu, F.L.; Lee, C.C.; Chen, T.C.; Ahmed A.A.A.; Sytwu, H.K.; Chang, D.M.; Huang, H.S.* Modified salicylanilide and 3-phenyl-2H-benzo[e][1,3]oxazine-2,4(3H)-dione derivatives as novel inhibitors of osteoclast differentiation and bone resorption, J. Med. Chem., 2014, 57, 8072-8085.
  81. Chen, C.L.; Liu, F.L.; Lee, C.C.; Chen, T.C.; Chang, W.W.; Guh, J.H.; Ahmed A.A.A.; Chang, D.M.*; Huang, H.S.* Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents, Eur. J. Med. Chem., 2014, 87, 30-38.
  82. Chen, Y.W.; Huang, H.S.; Shieh, Y.S.; Ma, K.H.; Huang, S.H.; Hueng, D.Y.; Sytwu, H.K.; Lin, G.J.* A Novel Compound NSC745885 Exerts an Anti-tumor Effect on Tongue Cancer SAS Cells in Vitro and in Vivo, Plos One, 2014, 9(8), e104703.
  83. Hsu, J.L.; Liu, S.P.; Lee, C.C.; Hsu, L.C.; Ho, Y.F.; Huang, H.S.*; Guh, J.H.* A unique amidoanthraquinone derivative displays anti-proliferative activity against human hormone-refractory metastatic prostate cancers through activation of LKB1-AMPK-mTOR signaling pathway, N-S. Arch Pharmacol., 2014, 387, 979-990.
  84. Tang, S.H.; Huang, H.S.; Wu, H.U.; Tsai, Y.T.; Chuang, M.J.; Chang, S.Y.; Yu, C.P.; Hsiao, P.W.; Sun, G.H.; Yu, D.S.; Cha, T.L.* Pharmacological down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo, Oncotarget, 2014, 5(21), 10342-10355.
  85. Liou, J.T.; Huang, H.S.; Chiang, M.L.; Lin, C.S.; Yang, S.P.; Ho, L.J.; Lai, J.H.*, A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells, Eur. J. Pharmacol., 2014, 726, 124-132.
  86. Chung, Y.L.; Pan, C.H.; Lioua, W.H.; Sheua, M.J.; Lin, W.H.; Chen, T.C.; Huang, H.S.; Wu, C.H.* NSC746364, a G-quadruplex stabilizing agent, suppresses cell growth of A549 human lung cancer cells through activation of ATR/Chk1-dependent pathway, J. Pharmacol. Sci., 2014, 124(1), 7-17.
  87. Lee, C.C.; Chang, D.M.; Huang, K.F.; Chen, C.L.; Chen, T.C.; Lo, Y.; Guh, J.H.*; Huang, H.S.* Design, synthesis and antiproliferative evaluation of fluorenone analogs with DNA topoisomerase I inhibitory properties, Bioorg. Med. Chem., 2013, 21, 7125-7133.
  88. Chen, T.C.; Yu, D.S.; Huang, K.F.; Fu, Y.C.; Chen, C.L.; Lee, C.C.; Huang, F.C.; Hsieh, H.H.; Lin, J.J.*; Huang, H.S.* Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agent, Eur. J. Med. Chem., 2013, 69, 278-293.
  89. Liou, W.S.; Hsieh, S.C.; Chang, W.Y.; Wu, H.M.G.; Huang, H.S.; Lee, C.F.* Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the national health insurance reimbursement database, Pharmacoepidemiol Drug Saf., 2013, 22, 752–759.
  90. Wang, C.H.; Huang, H.S.; Dai, N.T.; Sheu, M.J.; Chang, D.M.* Ascorbigen induces dermal papilla cell proliferation in vitro, but fails to modulate chemotherapy-induced alopecia in vivo, Phytother. Res., 2013, 27, 1863-1867.
  91. Lee, Y.R.; Yu, D.S.; Liang, Y.C.; Huang, K.F.; Chou, S.J.; Chen, T.C.; Lee, C.C.; Chen, C.L.; Chiou, S.H.*; Huang, H.S.* New approaches of PARP-1 inhibitors in human lung cancer cell lines and cancer stem-like cells caused by some selected anthraquinone-derived small molecules, Plos One, 2013, 8(2), e56284.
  92. Chen, C.L.; Chang, D.M.; Chen, T.C.; Lee, C.C.; Hsieh, H.H.; Huang, F.C.; Huang, K.F.; Guh, J.H.; Lin, J.J.*; Huang, H.S.* Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology, Eur. J. Med. Chem., 2013, 60, 29-41.
  93. Lee, C.C.; Huang, K.F.; Chang, D.M.; Hsu, J.J.; Huang, F.C.; Shih, K.N.; Chen, C.L.; Chen, T.C.; Chen, R.H.; Lin, J.J.*; Huang, H.S.* Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones, Eur. J. Med. Chem., 2012, 50, 102-112.
  94. Lee, C.C.; Huang, K.F.; Lin, P.Y.; Huang, F.C.; Chen, C.L.; Chen, T.C.; Guh, J.H.; Lin, J.J.*; Huang, H.S.* Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives, Eur. J. Med. Chem., 2012, 47, 323-336.
  95. Huang, F.C.; Huang, K.F.; Chen, R.H.; Wu, J.E.; Chen, T.C.; Chen, C.L.; Lee, C.C.; Chen, J.Y.; Lin, J.J.*; Huang, H.S.* Synthesis, telomerase evaluation and anti-proliferative studies on various series of diaminoanthraquinone-linked aminoacyl residues derivatives, Arch. Pharm., 2012, 345, 101-111.
  96. Cheng, C.P.; Huang, H.S.; Hsu, Y.C.; Sheu, M.J.; Chang, D.M.* Benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for rheumatoid arthritis, J. Clin. Immunol., 2012, 32, 762-777.
  97. Cheng, M.H.; Yang, Y.C.; Wong, Y.H.; Chen, T.R.; Lee, C.Y.; Yang, C.C.; Chen, S.H.; Yang, I.N.; Yang, Y.S.; Huang, H.S.; Yang, C.Y.; Huang, M.S.; Chiu, H.F.* B1, A novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells, Anti-Cancer Drug, 2012, 23(2), 191-199.
  98. Chang, Y.L.; Lee, H.J.; Liu, S.T.; Lin, Y.S.; Chen, T.C.; Hsieh, T.Y.*; Huang, H.S.*; Huang, S.M.*, Different roles of p53 in the regulation of DNA damage caused by 1,2-heteroannelated anthraquinones and doxorubicin, Int. J. Biochem. Cell B., 2011, 43, 1720-1728.
  99. Chang, C.J.; Hsu, C.C.; Chang, C.H.; Tsai, L.L.; Chang, Y.C.; Lu, S.W.; Yu, C.H.; Huang, H.S.; Wang, J.J.; Tsai, C.H.; Chou, M.Y.; Yu, C.C.; Hu, F.W. Let-7d functions as novel regulator of epithelial-mesenchymal transition and chemoresistant property in oral cancer, Oncol. Rep. 2011, Oct; 26(4), 1003-1010.
  100. Liu, F.C.; Huang, H.S.; Huang, C.Y.; Ro, Y.; Chang, D.M.; Lai, J.H.; Ho, L.J.*, A benzamide-linked small molecule HS-Cf inhibits TNF-α-induced Interferon Regulatory Factor-1 in porcine chondrocytes: A potential disease-modifying drug for osteoarthritis therapeutics, J. Clin. Immunol., 2011, 31, 6, 1131-1142.
  101. Chiang, C.H.; Chang, C.C.; Huang, H.C.; Tsai, P.H.; Jeng, S.Y.; Hung, S.I.; Liang, Y.C.; Huang, H.S.; Chiou, S.H.; Lee, F.Y.; Lee, S.D.; Yuan, C.C.; Hsieh, J.H. Investigation of hepatoprotective activity of induced pluripotent stem cells in the mouse model of liver injury, Journal of Biomedicine and Biotechnology, 2011, 2011: 219060.
  102. Shchekotikhin, A.E.; Glazunova, V.A.; Dezhenkova, L.G.; Shevtsova, E.K.; Traven, V.F.; Balzarini, J.; Huang, H.S.; Shtil, A.A.; Preobrazhenskaya, M.N. The first series of 4,11-bis[(2-aminoethyl)amino]anthrax[2,3-B]furan-5,10-diones: synthesis and anti-proliferative characteristics, Eur. J. Med. Chem., 2011, 46(1), 423-428.
  103. Huang, H.S.*; Huang, K.F.; Lee, C.C.; Chen, C.L.; Li, C.L.; Lin, J.J. NSC746364, NSC746365 and NSC746366: the spectra of cytotoxicity and molecular correlates of response to telomerase activity, Anti-Cancer Drug, 2010, 21(2), 169-180.
  104. Dutikova, Y.V.; Borisova, О.F.; Shchyolkina, А.К.; Lin, J.J.; Huang, H.S.; Shtil, А.А.; Kaluzhny, D.N. 5,10,15,20-Tetra-(N-methyl-3-pyridyl)porphyrin destabilizes the anti-parallel telomeric quadruplex d(TTAGGG)4, Mol. Biol+, 2010, 44, 5, 823-831.
  105. Shchekotikhin, A.E.; Dezhenkova, L.G.; Glazunova, V.A.; Kaluzhny, D.N.; Ilyinsky, N.S.; Shtil, A.A.; Preobrazhenskaya, M.N.; Lin, J.J.; Huang, H.S.* Novel anthrathiophene derivatives bind telomeric G-quadruplex and inhibit telomerase, ANNALS OF ONCOLOGY, 2010, 21, 32-33.
  106. Chou, Y.S.; Horng, C.T.; Huang, H.S.; Chen, J.T.; Tsai, M.L. Reactive arthritis following streptococcus viridian urinary tract infection, Ocul. Immunol. Inflamm., 2010, 18(1), 41-42.
  107. Huang, H.S.*; Chen, J.C.; Chen, R.H.; Huang, K.F.; Huang, F.C.; Jhan, J.R.; Chen, C.L.; Lo, Y.; Lee, C.C.; Lin, J.J.* Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues, Bioorg. Med. Chem., 2009, 17, 7418-7428.
  108. Shchekotikhin, A.E.*; Glazunova, V.A.; Dezhenkova, L.G.; Luzikov, Y.N.; Sinkevich, Y.B.; Kovalenko, L.V.; Buyanov, V.N.; Balzarini, J.; Huang, F.C.; Lin, J.J.; Huang, H.S.; Shtil, A.A.; Preobrazhenskaya, M.N. Synthesis and cytotoxic properties of 4,11-bis[(aminoethyl)amino]anthra-[2,3-b]thiophene-5,10-diones, novel analogues of antitumor anthracene-9,10-diones, Bioorg. Med. Chem., 2009, 17, 1861-1869.
  109. Huang, H.S.*; Huang, K.F.; Li, C.L.; Huang, Y.Y.; Chiang, Y.H.; Huang, F.C.; Lin, J.J.* Synthesis, human telomerase inhibition and antiproliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives, Bioorg. Med. Chem., 2008, 16, 6976-6986.
  110. Shchekotikhin, A.E.; Dezhenkova, L.G.; Susova, O.Y.; Glazunova, V.A.; Shtil, A.A.; Preobrazhenskaya, M.N.; Huang, H.S.* Novel naphthoindoledione derived topoisomerase I inhibitors: Potent for multidrug resistant tumor cells, ANNALS OF ONCOLOGY, 19, 28.
  111. Huang, H.S.*; Lin, J.J.; Huang, K.F.; Li, C.L. A Concise paradigm for the construction of amide linker of 2,7-diamidoanthraquinone derivatives as potential telomerase inhibitors, Taiwan Pharm. J., 2007, 59, 179-187.
  112. Cheng, K.T.; Hsu, F.L.; Chen, S.H.; Hsieh, P.K.; Huang, H.S.; Lee, C.K.; Lee, M.H.* New constituent from Podocarpus macrophyllus var. macrophyllus shows anti-tyrosinase effect and regulates tyrosinase-related proteins and mRNA in human epidermal melanocytes, Chem. Pharm. Bull. 2007, 55(5), 757-761.
  113. Huang, H.S.*; Chen, I.B.; Huang, K.F.; Lu, W.C.; Shieh, F.Y.; Huang, Y.Y.; Huang, F.C.; Lin, J.J.* Synthesis and human telomerase inhibition of a series of regioisomeric disubstituted amidoanthraquinones, Chem. Pharm. Bull. 2007, 55(2), 284-292.
  114. Preobrazhenskaya, N.M.; Tevyashova, A.N.; Olsufyeva, E.N.; Huang, K.F.; Huang, H.S. Second generation drugs-derivatives of natural antitumor anthracycline antibiotics daunorubicin, doxorubicin and carminomycin, J. Med. Sci. 2006, 26(4), 119-128.
  115. Huang, H.S.*; Chiu, H.F.; Tao, C.W.; Chen, I.B. Synthesis and antitumor evaluation of symmetrical 1,5-diamidoanthraquinone derivatives as compared to their disubstituted homologues, Chem. Pharm. Bull. 2006, 54(4), 458-464.
  116. Preobrazhenskaya, N.M.; Shchekotikhin, A.E.; Shtil, A.A.; Huang, H.S.* Antitumor anthraquinone analogues for multidrug resistant tumor cells, J. Med. Sci. 2006, 26(1), 1-4.
  117. Huang, H.S.*; Chiu, H.F.; Lu, W.C.; Yuan, C.L. Synthesis and antitumor activity of 1,8-diaminoanthraquinone derivatives, Chem. Pharm. Bull. 2005, 53(9), 1136-1139.
  118. Huang, H.S.*; Chou, C.L.; Guo, C.L.; Yuan, C.L.; Lu, Y.C.; Shieh, F.Y.; Lin, J.J. Human telomerase inhibition and cytotoxicity of regioisomeric disubstituted amidoanthraquinones and aminoanthraquinones, Bioorg. Med. Chem. 2005, 13, 1435-1444. (Publisher's Announcement—Tetrahedron Prize for Creativity in Organic Chemistry for 2004)
  119. Huang, H.S.*; Chiu, H.F.; Lee, A.R.; Guo, C.L.; Yuan, C.L. Synthesis and structure-activity correlations of the cytotoxic bifunctional 1,4-diamidoanthraquinone derivatives, Bioorg. Med. Chem. 2004, 12, 6163-6170.
  120. Huang, H.S.*; Chiu, H.F.; Yeh, P.F.; Yuan, C.L. Structure-based design and synthesis of regioisomeric disubstituted aminoanthraquinone derivatives as potential anticancer agents, Helvetica Chimica Acta, 2004, 87, 999-1006.
  121. Chen, R.F.; Chou, C.L.; Wang, M.R.; Chen, C.F.; Liao, J.F.; Ho, L.K.; Tao, C.W.; Huang, H.S.* Small-Molecule Anthracene-induced Cytotoxicity and Induction of Apoptosis through Generation of ROS, Biol. Pharm. Bull. 2004, 27(6), 838-845.
  122. Lin, L.H.; Huang, H.S.; Lin, C.C.; Lee, L.W.; Lin, P.Y. Effects of Cantharidinimides on Human Carcinoma Cells, Chem. Pharm. Bull. 2004, 52(7), 855-857.
  123. Chen, R.F.; Shen, Y.C.; Huang, H.S.; Liao, J.F.; Ho, L.K.; Chou, Y.C.; Wang, W.Y.; Chen, C.F.* Evaluation of the anti-inflammatory and cytotoxic effects by anthraquinone and anthracene derivatives in human leukocytes, J. Pharm. Pharmacol. 2004, 56(7), 915-919.
  124. Huang, H.S.*; Chiou, J.F.; Fong, Y.; Hou, C.C.; Lu, Y.C.; Wang, J.Y.; Shih, J.W.; Pan, Y.R.; Jeng, W.R.; Lin, J.J. Activation of human telomerase reverse transcriptase expression by some new symmetrical bis-substituted derivatives of the anthraquinone, J. Med. Chem. 2003, 46, 3300-3307.
  125. Huang, H.S.*; Chiou, J.F.; Chiu, H.F.; Chen, R.F.; Lai, Y.L. Synthesis and cytotoxicity of 9-alkoxy-1,5-dichloroanthracene derivatives in murine and human cultured tumor cells, Arch. Pharm. 2002, 335(1), 33-38.
  126. Huang, H.S.*; Chiou, J.F.; Chiu, H.F.; Tao, C.W.; Chen, R.F.; Jeng, W.R. Synthesis of symmetrical 1,5-bisacyloxy anthraquinone derivatives and their dual activity of cytotoxicity and lipid peroxidation, Arch. Pharm. 2002, 335(10), 481-486.
  127. Huang, H.S.*; Chiou, J.F.; Chiu, H.F.; Tao, C.W.; Yeh, P.F.; Jeng, W.R. Synthesis of symmetrical 1,5-bisthiosubstituted anthraquinones for cytotoxicity in cultured tumor cells and lipid peroxidation, Chem. Pharm. Bull. 2002, 50(11), 1491-1494.
  128. Huang, H.S.*; Hwang, J.M.; Jen, Y.M.; Lin, J.J.; Lee, K.Y.; Shi, C.H.; Hsu, H.C. Studies on anthracenes. 1. Human telomerase inhibition and lipid peroxidation of 9-acyloxy 1,5-dichloroanthracene derivatives, Chem. Pharm. Bull. 2001, 49(8), 969-973.
  129. Huang, H.S.*; Chiu, H.F.; Hwang, J.M.; Jen, Y.M.; Tao, C.W.; Lai, Y.L. Studies on anthracenes. 2. Synthesis and cytotoxic evaluation of 9-acyloxy 1,8-dichloroanthracene derivatives, Chem. Pharm. Bull. 2001, 49(10), 1346-1348.
  130. Huang, H.S.*; Lin, P.Y.; Hwang, J.M.; Hsu, H.C.; Lai, Y.L.; Tao, C.W. Studies on anthracenes. 3. Synthesis, lipid peroxidation and cytotoxic evaluation of 10-substituted 1,5-dichloro-9(10H)-anthracenone derivatives, Chem. Pharm. Bull. 2001, 49(10), 1288-1291.
  131. Huang, H.S.*; Hwang, J.M.; Jen, Y.M.; Tao, C.W.; Lee, K.Y.; Shi, C.H. Chromophore-modified antitumor anthracenes. 1. Cytotoxic activity of 9-acyloxy 1,5-dichloroanthracene analogues, Chin. Pharm. J. 2001, 53, 2, 71-83.
  132. Huang, H.S.*; Lin, P.Y. Chemical characterization of novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenone derivatives by mass spectrometry, Proc. Natl. Sci. Counc. ROC(B), 2000, 24, 1, 45-51.
  133. Hwang, J.M.; Huang, H.S.; Hsu, W.L.; Shueng, P.W.; Lee, W.H. Effects of radiation and BSO on GSH concentration of GBM cells, Therap. Radiol. & Oncol. 2000, 7(1), 1-8.
  134. Huang, H.S.*; Lee, A.L.; Wu, C.C.; Yen, M.H.; Hwang, J.M. Oxidative chemistry and chemical biology of superoxide, nitric oxide and peroxynitrite, J. Med. Sci. 1999, 20(3):111-123.
  135. Huang, H.S.*; Studies on the anti-psoriatic activities and spectroscopy of 10-benzylthio-anthralin and its deuterated analogs. Chin. Pharm. J. 1998, 50, 267-276.
  136. Huang, H.S.*; Clinical treatments for psoriasis, J. of Hospital Pharmacy, 1998, 170-182.
  137. Wu, C.C.; Luk, H.N.; Huang, H.S.; Chueh, S.H.; Lin, C.I.; Yen, M.H. Investigation of pathogenesis and treatment of septic shock: different approach from physiology, biochemistry, drugs and pharmacology, J. Med. Sci. 1998, 19(3):135-140.
  138. Müller, K.; Huang, H.S.; Wiegrebe, W. Preparation of 10-thio-substituted 1,8-dihydroxy-9(10H)-anthracenones for use in the treatment of inflammatory conditions, Chem. Abstr. 1997, 126, 131259j.
  139. Müller, K.; Prinz, H.; Gawlik, I.; Ziereis, K.; Huang, H.S. Simple analogs of anthralin: Unusual specificity of structure and antiproliferative activity, J. Med. Chem. 1997, 40, 23, 3773-3780.
  140. Huang, H.S.* Synthesis, chemical characterization, and biological evaluation of novel 10-thio-substituted 1,8-dihydroxy-9(10H)-anthracenones, Ph.D. Thesis, 1996, University Regensburg, Germany.
  141. Müller, K.; Huang, H.S.; Wiegrebe, W. Antipsoriatic anthrones with modulated redox properties. 3. 10-thio-substituted 1,8-dihydroxy-9(10H)-anthracenone as inhibitors of keratinocyte growth, 5-lipoxygenase, and the formation of 12(S)-HETE in mouse epidermis, J. Med. Chem. 1996, 39, 16, 3132-3138.
  142. Müller, K.; Huang, H.S.* Development of novel antipsoriatic anthrones, Chin. Pharm. J. 1996, 48, 337-354.
  143. Huang, H.S.*; Mayer, K.K.; Wiegrebe, W. Electron-impact induced and thermal decomposition of dithranol derivatives, III: Fragmentations of 10-alkoxy- and 10-benzyloxy-dithranol radical cations, Arch. Pharm. 1995, 328, 297-299.
  144. Huang, H.S.*; Mayer, K.K.; Wiegrebe, W. Electron-impact induced and thermal decomposition of dithranol derivatives, I: Thermolysis of 10-phenylthio-dithranol in the mass spectrometer, Arch. Pharm. 1994, 327, 669-671.
  145. Huang, H.S.*; Mayer, K.K.; Wiegrebe, W. Electron-impact induced and thermal decomposition of dithranol derivatives, II: Multiple H-rearrangements in 10-benzylthio-dithranol radical cations, Arch. Pharm. 1994, 327, 735-738.
  146. Huang, H.S.*; Mayer, K.K.; Müller, K.; Wiegrebe, W. A convenient synthesis of 14C-anthralin, Arch. Pharm. 1994, 327, 743-744.
  147. Liu, K.C.; Huang, H.S. Cyclocondensation of 2-aminoperimidine hydrobromide with representative 1,3-bifunctional carboxylic esters, Chin. Pharm. J. 1993, 45, 203-213.
  148. Liu, K.C.; Huang, H.S.; Fan, L.T. Synthesis and biological evaluation of some representative 10-substituted 9,10-dihydro-8H-imidazo[1,2-a]- and 10-substituted-8H-1,2,4-triazolo-[4,3-a]perimidine derivatives, Chin. Pharm. J. 1993, 45, 511-518.
  149. Liu, K.C.; Huang, H.S. Synthesis of ethyl 4(1H)-oxopyrimido[1,2-a]perimidine-3-carboxylate, Arch. Pharm. 1989, 322, 303-304.
  150. Liu, K.C.; Huang, H.S.; Lin, S.M. Cyclocondensation of 2-hydrazinoperimide with ethyl ethoxymethylenecyanoacetate, Chin. Pharm. J. 1989, 41, 159-161.
  151. Liu, K.C.; Huang, H.S. Synthesis and biological evaluation of some 1-substituted 3-(2-perimidyl)ureas, Arch. Pharm. 1988, 321, 425-426.
  152. Liu, K.C.; Huang, H.S. Synthesis of methyl 4(1H)-oxopyrimido[1,2-a]perimidine-2-carboxylate, Arch. Pharm. 1988, 321, 771-772.
💡 Patents
※ Scroll down to view more
  1. Ka, S.M.; Huang, H.S.; Chen, A. Method for amellorating progression of renal fibrosis and treating renal fibrosis by 5-(2’,4’-difluorophenyl)-salicylanilide derivatives, US Patent No. 12,478,632 B2. Date of Patent: Nov. 25, 2025. 賈淑敏、黃旭山、陳安，一種用於緩解或預防慢性腎臟病進展的藥物組合物及其用途，證書號數：I821836，2023, Nov. 11.
  2. Huang, H.S.; Lee, H. Japan Patent No. 6337077. Date of Patent: May 11, 2018.
  3. Huang, H.S.; Yu, D.S.; Chen, T.C. Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors, European Patent No. 3002287B1. Date of Patent: Jan. 31, 2018; Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors, Russia Patent No. 2663929. Date of Patent: June 13, 2018; Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof, US Patent No. 8,927,717B1. Date of Patent: Jan. 6, 2015. Taiwan patent I488843 (2015)； WO2015120730A1； Korea KR20160043348A (2015); Australian Patent No. 2014240265, AU2014240265B2 (2015) ; Japan, JP6063909B2 (2016) ; New Zealand Patent No. 700644 (2016); China PRC Patent No. CN104356142B (2017); Canadian Patent No. 2866502, CA2866502C (2017)； EUROPEAN PATENT EP3002287B1 (2018); HK1206334; Russian Patent: 2663929; Spain: EP3002287, E14187461(0); Denmark: DK/EP3002287T3; Turkey: EP3002287B1, TR2018 05917T4 (Turk Patent, No: TR2018 05917 T4 (EP3002287B1)). Dehydrothiamine[2,3-c]quinoline-12-ketone derivatives and preparation method and application thereof, Patent No. HK 1206334. Date of Patent: June 8, 2018; PRC Patent No. ZL2014 1 0566281.7, Date of Filing: 2014/10/22, Date of Patent: Oct. 20, 2017; Japan Patent No. 6063909. Date of Patent: Dec. 22, 2016; Canadian Patent No. 2866502, Date of Patent: May 02, 2017; Australian Patent No. 2014240265. Date of Patent: Jan. 21, 2016; New Zealand Patent No. 700644. Date of Patent: Mar. 1, 2016.
  4. Huang, H.S. ROC Patent No.: I644687. Date of Patent: Dec. 21, 2018.
  5. Sun, W.H.; Huang, S.L.; Huang, H.S. Indication of naphtho[2,3-F]quinoxaline-7,12-dione compound in alleviating pain. USA US 9,284,281B2. Date of Patent: Mar. 15, 2016.
  6. Sun, W.H.; Huang, S.L.; Huang, H.S. Indication of anthra[2,1,c][1,2,5] thiadiazole-6,11-dione compound in alleviating pain, US Patent No. 9192602B2. Date of Patent: Nov. 24, 2015.
  7. Sun, W.H.; Huang, S.L.; Huang, H.S. ROC Patent No.: I492920. Date of Patent: July 21, 2015.
  8. Chang, D.M.; Huang, H.S.; Lee, Chia-Chung; Chen, Chun-Liang. Preparation and Pharmaceuticals of Biphenyl Benzamide-derived Derivatives, Date of Filing: 2015/01/29, US Patent No. 9162993B. Date of Patent: Oct. 20, 2015.
  9. Chang, D.M.; Huang, H.S.; Lee, Chia-Chung; Chen, Chun-Liang. Pharmaceutical composition of salicylanilide-derived small molecules and preparation and application thereof, US Patent No. 9018203. Date of Patent: April 28, 2015.
  10. Chang, D.M.; Huang, H.S.; Lee, Chia-Chung; Chen, Chun-Liang. Preparation and pharmaceuticals of biphenyl benzamide-derived derivatives, US Patent No. 8975255. Date of Patent: March 10, 2015.
  11. Huang, H.S.; Yu, D.S.; Chen, T.C. Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof, US Patent No. 8,927,717B1. Date of Patent: Jan. 6, 2015.
  12. Chang, D.M.; Huang, H.S.; Lee, C.C.; Chen, C.L. ROC Patent No.: I492920. Date of Patent: July 21, 2015.
  13. Huang, H.S.; Yu, D.S.; Chen, T.C. ROC Patent No.: I488843. Date of Patent: June 21, 2015.
  14. Huang, H.S. ROC Patent No.: I465423. Date of Patent: Dec. 21, 2014.
  15. Chang, D.M.; Huang, H.S. ROC Patent No.: I455711. Date of Patent: Oct. 11, 2014.
  16. Chang, D.M.; Huang, H.S.; Lee, C.C.; Chen, C.L. ROC Patent No.: I454445. Date of Patent: Oct. 1, 2014.
  17. Huang, H.S. ROC Patent No.: I435719. Date of Patent: May 1, 2014.
  18. Huang, H.S.; Chen, C.L. ROC Patent No.: I432192. Date of Patent: April 1, 2014.
  19. Huang, H.S. ROC Patent No.: I422367. Date of Patent: Jan. 11, 2014.
  20. Chang, D.M.; Huang, H.S. Pharmaceutical composition for inhibiting osteoclast growth, US Patent No. 8,772,344. Date of Patent: July 8, 2014.
  21. Huang, H.S.; Chen, T.C.; Cha, T.L. Heteroannelated anthraquinone derivatives for inhibiting cancers, US Patent No. 8,772,321. Date of Patent: July 8, 2014.
  22. Huang, H.S.; Lee, Y.R.; Chen, T.C. Heterocyclic fused anthraquinone derivatives, manufacturing method and pharmaceutical composition using thereof, US Patent No. 8,877,748. Date of Patent: Nov. 4, 2014.
  23. Huang, H.S.; Lee, C.C. 1,2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof, US Patent No. 8,530,465B2. Date of Patent: Sep. 10, 2013.
  24. Huang, H.S.; Lee, C.C. ROC Patent No.: I402066. Date of Patent: July 21, 2013.
  25. Huang, H.S. Substituted Naphto[2,3-F]quinoxaline-7,12-diones and Pharmaceutical Utility Thereof, US Patent No. 8,470,824 B2. Date of Patent: June 25, 2013.
  26. Huang, H.S. Method for Inhibiting Growth of Cancer Cells and Cell Telomere and Diseases of Cell Proliferation by Using Heteroannelated Anthraquinone Derivative Compounds, US Patent No. 8,445,492 B2. Date of Patent: May 21, 2013.
  27. Huang, H.S. Thioxanthone Ring System Derivatives, US Patent No. 8,410,161B2. Date of Patent: Apr. 02, 2013.
  28. Huang, H.S. Thioxanthone Ring System Derivatives, ROC Patent No.: I414520. Date of Patent: Nov. 11, 2013.
  29. Huang, H.S. ANTHRAIMIDAZOLE DERIVATIVES AND THE SYNTHESIS METHOD THEREOF, ROC Patent No.: I399369. Date of Patent: June 21, 2013.
  30. Huang, H.S. ROC Patent No.: I399399. Date of Patent: Feb. 21, 2013.
  31. Huang, H.S. ROC Patent No.: I378792. Date of Patent: Dec. 11, 2012.
  32. Huang, H.S.; Lee, C.C. 1,2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof, US Patent No. 8,304,415. Date of Patent: Nov. 06, 2012.
  33. Huang, H.S. Substituted Anthra[1,2-D]imidazolediones and Pharmaceutical Utility Thereof, US Patent No. 8,222,287. Date of Patent: July 17, 2012.
  34. Huang, H.S. Novel Anthra[1,2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof, US Patent No. 8,124,637 B2. Date of Patent: Feb. 28, 2012.
  35. Huang, H.S. Anti-Cancer Compound and Manufacturing Method Thereof, US Patent No. 8,053,583 B2. Date of Patent: Nov. 8, 2011.
  36. Huang, H.S. Thio-subsituted Anthra[1,2-d] imidazole-6,11-dione Dervatives, Preparation Method and application thereof, US Patent No. 8,067,454 B2. Date of Patent: Nov. 29, 2011.
  37. Huang, H.S. US Patent No. 6,596,774. Date of Patent: July 22, 2003.
  38. Huang, H.S. U.S. Patent No. 6,372,785 B1. Date of Patent: Apr. 16, 2002.
  39. Huang, H.S.; Lee, K.-Y.; Shi, C.-H.; Hsu, H.-C. U.S. Patent No. 6,369,246 B2. Date of Patent: Apr. 9, 2002.
  40. Müller, K.; Huang, H.S.; Wiegrebe, W. U.S. Patent No. 5,705,533. Date of Patent: Jan. 6, 1998.
  • 瀏覽人次:434
  • 更新日期:2026-03-24